142 related articles for article (PubMed ID: 9815936)
61. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.
Lewis LJ; Mistry P; Charlton PA; Thomas H; Coley HM
Anticancer Drugs; 2007 Feb; 18(2):139-48. PubMed ID: 17159600
[TBL] [Abstract][Full Text] [Related]
62. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
63. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors.
Sinha BK; Eliot HM
Biochim Biophys Acta; 1991 Sep; 1097(2):111-6. PubMed ID: 1655044
[TBL] [Abstract][Full Text] [Related]
64. Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Hirohashi Y; Hidaka K; Sato S; Kuwano M; Kohno K; Hisatsugu T
Jpn J Cancer Res; 1995 Nov; 86(11):1097-105. PubMed ID: 8567402
[TBL] [Abstract][Full Text] [Related]
65. Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells.
Allen GC; Lubas S; Wax MK; Devore RF
Otolaryngol Head Neck Surg; 1996 Jun; 114(6):785-92. PubMed ID: 8643303
[TBL] [Abstract][Full Text] [Related]
66. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
67. Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.
Eymin B; Dubrez L; Allouche M; Solary E
Cancer Res; 1997 Feb; 57(4):686-95. PubMed ID: 9044846
[TBL] [Abstract][Full Text] [Related]
68. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
[TBL] [Abstract][Full Text] [Related]
69. Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines.
Liu WM; Oakley PR; Joel SP
Leukemia; 2002 Sep; 16(9):1705-12. PubMed ID: 12200685
[TBL] [Abstract][Full Text] [Related]
70. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
71. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
Ishida R; Iwai M; Hara A; Andoh T
Anticancer Res; 1996; 16(5A):2735-40. PubMed ID: 8917380
[TBL] [Abstract][Full Text] [Related]
72. [Synergetic cytotoxicity of cisplatin and etoposide to leukemia cell line K562 and its mechanism].
Ma WD; Yin MY; Jiang CW; Xu SR; Zhai LD; Zheng LF; Wang YL; Yan YL
Ai Zheng; 2005 Aug; 24(8):958-64. PubMed ID: 16086873
[TBL] [Abstract][Full Text] [Related]
73. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.
Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG
Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572
[TBL] [Abstract][Full Text] [Related]
74. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
75. A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance.
Hill BT; Whelan RD; Hosking LK; Shellard SA; Hinds MD; Mayes J; Zwelling LA
Int J Cancer; 1991 Apr; 47(6):899-902. PubMed ID: 1849124
[TBL] [Abstract][Full Text] [Related]
76. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
77. Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16).
Rappa G; Shyam K; Lorico A; Fodstad O; Sartorelli AC
Oncol Res; 2000; 12(3):113-9. PubMed ID: 11216669
[TBL] [Abstract][Full Text] [Related]
78. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
[TBL] [Abstract][Full Text] [Related]
79. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
80. Altered expression of DNA-topoisomerase IIalpha is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells.
Melixetian MB; Beryozkina EV; Pavlenko MA; Grinchuk TM
Leuk Res; 2000 Oct; 24(10):831-7. PubMed ID: 10996201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
